Literature DB >> 22426087

Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis.

Rebecca M Lovell1, Alexander C Ford.   

Abstract

BACKGROUND & AIMS: Many cross-sectional surveys have reported the prevalence of irritable bowel syndrome (IBS), but there have been no recent systematic review of data from all studies to determine its global prevalence and risk factors.
METHODS: MEDLINE, EMBASE, and EMBASE Classic were searched (until October 2011) to identify population-based studies that reported the prevalence of IBS in adults (≥15 years old); IBS was defined by using specific symptom-based criteria or questionnaires. The prevalence of IBS was extracted for all studies and based on the criteria used to define it. Pooled prevalence, according to study location and certain other characteristics, odds ratios (ORs), and 95% confidence intervals (CIs) were calculated.
RESULTS: Of the 390 citations evaluated, 81 reported the prevalence of IBS in 80 separate study populations containing 260,960 subjects. Pooled prevalence in all studies was 11.2% (95% CI, 9.8%-12.8%). The prevalence varied according to country (from 1.1% to 45.0%) and criteria used to define IBS. The greatest prevalence values were calculated when ≥3 Manning criteria were used (14%; 95% CI, 10.0%-17.0%); by using the Rome I and Rome II criteria, prevalence values were 8.8% (95% CI, 6.8%-11.2%) and 9.4% (95% CI, 7.8%-11.1%), respectively. The prevalence was higher for women than men (OR, 1.67; 95% CI, 1.53-1.82) and lower for individuals older than 50 years, compared with those younger than 50 (OR, 0.75; 95% CI, 0.62-0.92). There was no effect of socioeconomic status, but only 4 studies reported these data.
CONCLUSIONS: The prevalence of IBS varies among countries, as well as criteria used to define its presence. Women are at slightly higher risk for IBS than men. The effects of socioeconomic status have not been well described.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22426087     DOI: 10.1016/j.cgh.2012.02.029

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  540 in total

Review 1.  Meditation over medication for irritable bowel syndrome? On exercise and alternative treatments for irritable bowel syndrome.

Authors:  Fredrick Asare; Stine Störsrud; Magnus Simrén
Journal:  Curr Gastroenterol Rep       Date:  2012-08

2.  Genome-wide DNA methylation profiling of peripheral blood mononuclear cells in irritable bowel syndrome.

Authors:  S Mahurkar; C Polytarchou; D Iliopoulos; C Pothoulakis; E A Mayer; L Chang
Journal:  Neurogastroenterol Motil       Date:  2015-12-16       Impact factor: 3.598

3.  Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern.

Authors:  A M Su; W Shih; A P Presson; L Chang
Journal:  Neurogastroenterol Motil       Date:  2013-08-29       Impact factor: 3.598

Review 4.  A Systematic Review of the Effects of Polyols on Gastrointestinal Health and Irritable Bowel Syndrome.

Authors:  Adrienne Lenhart; William D Chey
Journal:  Adv Nutr       Date:  2017-07-14       Impact factor: 8.701

Review 5.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

Review 6.  Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis.

Authors:  Andrew J Irvine; William D Chey; Alexander C Ford
Journal:  Am J Gastroenterol       Date:  2016-10-18       Impact factor: 10.864

Review 7.  Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology.

Authors:  Nicholas J Talley; Gerald Holtmann; Marjorie M Walker
Journal:  J Gastroenterol       Date:  2015-04-29       Impact factor: 7.527

8.  Lack of utility of symptoms and signs at first presentation as predictors of inflammatory bowel disease in secondary care.

Authors:  Alexander C Ford; Paul Moayyedi; Premysl Bercik; David G Morgan; Carolina Bolino; Maria I Pintos-Sanchez; Walter Reinisch
Journal:  Am J Gastroenterol       Date:  2015-04-28       Impact factor: 10.864

9.  Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome.

Authors:  Johanna Iturrino; Michael Camilleri; Irene Busciglio; Duane Burton; Alan R Zinsmeister
Journal:  Dig Liver Dis       Date:  2013-10-04       Impact factor: 4.088

Review 10.  Intestinal microbiota and its role in irritable bowel syndrome (IBS).

Authors:  Lena Ohman; Magnus Simrén
Journal:  Curr Gastroenterol Rep       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.